Symptom and quality of life improvement in LUX-lung 6: An open-label Phase III study of afatinib versus cisplatin/gemcitabine in asian patients with EGFR mutation-positive advanced non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 10, Issue 6, 2015, Pages 883-889

  Geater, Sarayut L ^a   Xu, Chong Rui ^b   Zhou, Caicun ^c   Hu, Cheng Ping ^d   Feng, Jifeng ^e   Lu, Shun ^f   Huang, Yunchao ^g   Li, Wei ^h   Hou, Mei ⁱ   Shi, Jian Hua ^j   Lee, Kye Young ^k   Palmer, Michael ^l   Shi, Yang ^m   Lungershausen, Juliane ⁿ   Wu, Yi Long ^b  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c TONGJI UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e Jiangsu Provincial Tumor Hospital   (China)

^f SHANGHAI JIAO TONG UNIVERSITY   (China)

^g KUNMING MEDICAL UNIVERSITY   (China)

^h THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

ⁱ SICHUAN UNIVERSITY   (China)

^j LINYI CANCER HOSPITAL   (China)

^k Konkuk University Hospital   (South Korea)

^l KEELE UNIVERSITY   (United Kingdom)

^m Boehringer Ingelheim International Trading Co Ltd   (China)

ⁿ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

Afatinib; Non small cell lung cancer; Patient reported outcomes; Progression free survival; Quality of life

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; CISPLATIN PLUS GEMCITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG; CISPLATIN; DEOXYCYTIDINE; EGFR PROTEIN, HUMAN; GEMCITABINE; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHRONOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; COUGHING; DETERIORATION; DRUG EFFICACY; DYSPNEA; FEMALE; GENE MUTATION; HUMAN; LONGITUDINAL STUDY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84938253260     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000517     Document Type: Conference Paper

References (23)

1. Hirsch FR, Jänne PA, Eberhardt WE, Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 2013 8 373 384
2. Li D, Ambrogio L, Shimamura T, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008 27 4702 4711
3. Solca F, Dahl G, Zoephel A, Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012 343 342 350
4. Sequist LV, Yang JC, Yamamoto N, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013 31 3327 3334
5. Wu YL, Zhou C, Hu CP, Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014 15 213 222
6. Yang JC, Wu YL, Schuler M, Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015 16 141 151
7. Miller VA, Hirsh V, Cadranel J, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012 13 528 538
8. Katakami N, Atagi S, Goto K, LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013 31 3335 3341
9. Fallowfield LJ, Fleissig A., The value of progression-free survival to patients with advanced-stage cancer. Nat Rev Clin Oncol 2012 9 41 47
10. Gutman SI, Piper M, Grant MD, Progression-free survival: what does it mean for psychological well-being or quality of life? 2013 Rockville (MD) Agency for Healthcare Research and Quality (US). Report No: 13-EHC074-EF
11. Yang JC, Hirsh V, Schuler M, Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013 31 3342 3350
12. Langer CJ., Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol 2013 31 3303 3306
13. Claassens L, van Meerbeeck J, Coens C, Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol 2011 29 2104 2120
14. Aaronson NK, Ahmedzai S, Bergman B, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993 85 365 376
15. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M., The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994 30A 635 642
16. Hirsh V, Cadranel J, Cong XJ, Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol 2013 8 229 237
17. Fayers PM, Aaronson NK, Bjordal K, The EORTC QLQ-C30 scoring manual 2001. Available at: http://www.eortc.be/qol/files/SCManualQLQ-c30.pdf. Accessed February 26, 2014
18. Osoba D, Rodrigues G, Myles J, Zee B, Pater J., Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998 16 139 144
19. Fairclough DL., Design and analysis of quality of life studies in clinical trials 2010 London Chapman & Hall
20. Diggle P, Heagerty P, Liang K-Y, Analysis of Longitudinal Data 2002 Oxford Oxford University Press
21. Griebsch I, Palmer M, Fayers PM, Ellis S., Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib. BMJ Open 2014 4 e005762
22. Damm K, Roeske N, Jacob C., Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health Econ Rev 2013 3 15
23. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM., Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 2011 29 89 96